Preoperative Chemoradiotherapy for Resectable Gastric Cancer
New England Journal of Medicine · 14.11.2024 · 391 (19) · 1810-1821
DOI: 10.1056/nejmoa2405195 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, erschienen am 14.11.2024. Verfasst von Trevor Leong und 22 weiteren Autor:innen. Beteiligte Einrichtung: From the Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, University of Melbourne (T.L., M.M., W.K.M.), the School of Publi…. Hauptthemen laut MEDLINE: Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols, Esophagogastric Junction, Stomach Neoplasms. Die Arbeit wurde bisher 132-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: CIHR, National Health and Medical Research Council, Health Research Council of New Zealand.
Abstract (Originalsprache)
BACKGROUND: In Western countries, the current standard of care for resectable gastric cancer is perioperative chemotherapy. Preoperative chemoradiotherapy has been considered, but data are limited regarding this treatment as compared with perioperative chemotherapy alone. METHODS: We conducted an international, phase 3 trial in which patients with resectable adenocarcinoma of the stomach or gastroesophageal junction were randomly assigned to receive preoperative chemoradiotherapy plus perioperative chemotherapy or perioperative chemotherapy alone (control). In both groups, patients received either epirubicin, cisplatin, and fluorouracil or fluorouracil, leucovorin, oxaliplatin, and docetaxel both before and after surgery; the preoperative-chemoradiotherapy group also received chemoradiotherapy (45 Gy in 25 fractions of radiation, plus fluorouracil infusion). The primary end point was overall survival, and secondary end points included progression-free survival, pathological complete response, toxic effects, and quality of life. RESULTS: A total of 574 patients underwent randomization at 70 sites in Australasia, Canada, and Europe: 286 to the preoperative-chemoradiotherapy group and 288 to the perioperative-chemotherapy group. A higher percentage of patients in the preoperative-chemoradiotherapy group than in the perioperative-chemotherapy group had a pathological complete response (17% vs. 8%) and greater tumor downstaging after resection. At a median follow-up of 67 months, no significant between-group differences in overall survival or progression-free survival were noted. The median overall survival was 46 months with preoperative chemoradiotherapy and 49 months with perioperative chemotherapy (hazard ratio for death, 1.05; 95% confidence interval, 0.83 to 1.31), and the median progression-free survival was 31 months and 32 months, respectively. Treatment-related toxic effects were similar in the two groups. CONCLUSIONS: The addition of preoperative chemoradiotherapy to perioperative chemotherapy did not improve overall survival as compared with perioperative chemotherapy alone among patients with resectable gastric and gastroesophageal junction adenocarcinoma. (Funded by the National Health and Medical Research Council and others; TOPGEAR ClinicalTrials.gov number, NCT01924819.).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, University of Melbourne (T.L., M.M., W.K.M.), the School of Public Health, Monash University (J.Z.), the Department of Medical Oncology…
ORCID-Profile: John Simes
Förderung
- CIHR
- National Health and Medical Research Council
- Health Research Council of New Zealand
- Canadian Cancer Society Research Institute
- Cancer Australia
- Canadian Institutes of Health Research
- Cancer Australia Priority-driven Collaborative Research Scheme
- EORTC Cancer Research Fund
Zitieren
APA
Leong, T., Smithers, B. M., Michael, M., Haustermans, K., Wong, R., Gebski, V., O'Connell, R. L., Zalcberg, J., Boussioutas, A., Findlay, M., Willis, D., Moore, A., Murray, W. K., Lordick, F., O'Callaghan, C., Swallow, C., Darling, G., Miller, D., Strickland, A., …, & Australasian Gastro-Intestinal Trials Group, National Health and Medical Research Council Clinical Trials Centre, Trans-Tasman Radiation Oncology Group, Europe… (2024). Preoperative Chemoradiotherapy for Resectable Gastric Cancer. New England Journal of Medicine, 391(19), 1810-1821. https://doi.org/10.1056/nejmoa2405195
Vancouver
Leong T, Smithers BM, Michael M, Haustermans K, Wong R, Gebski V, et al. Preoperative Chemoradiotherapy for Resectable Gastric Cancer. New England Journal of Medicine. 2024;391(19):1810-1821. doi:10.1056/nejmoa2405195
BibTeX
@article{Leong2024,
author = {Leong, Trevor and Smithers, B Mark and Michael, Michael and Haustermans, Karin and Wong, Rebecca and Gebski, Val and O'Connell, Rachel L and Zalcberg, John and Boussioutas, Alex and Findlay, Michael and Willis, David and Moore, Alisha and Murray, William K and Lordick, Florian and O'Callaghan, Chris and Swallow, Carol and Darling, Gail and Miller, Danielle and Strickland, Andrew and Liberman, Moishe and Mineur, Laurent and Simes, John and Australasian Gastro-Intestinal Trials Group, National Health and Medical Research Council Clinical Trials Centre, Trans-Tasman Radiation Oncology Group, Europe…, Australasian Gastro-Intestinal Trials Group, National Health and Medical Research Council Clinical Trials Centre, Trans-Tasman Radiation Oncology Group, Europe…},
title = {Preoperative Chemoradiotherapy for Resectable Gastric Cancer},
journal = {New England Journal of Medicine},
year = {2024},
volume = {391},
number = {19},
pages = {1810--1821},
doi = {10.1056/nejmoa2405195}
}
EUVIMED